Hubei Goto Biopharm Co.,Ltd.'s low P/S ratio may be due to anticipated poor revenue performance. The company's recent revenue trends are less appealing compared to industry growth forecasts. Investors might pay less for the stock, expecting limited future growth rates.
共同药业股票讨论区
暂无评论